Stan Thanks everyone. afternoon good and
just against Given our programs of which strains over the provide more demonstrated market comparison demonstrated clinical our our influenza RSV's an studies. the significantly Starting superior of influenza a and together and seasons. series that with the In of X discussed we head-to-head a compared quarterly in broader flu our that immunogenicity nanoparticle that overview including drifted we showing NanoFlu our of preclinical detailed overview matched provided I'll Phase studies quarter, vaccine influenza NanoFlu with quick unmatched decade here program the we adult results the proprietary nanoparticle vaccine high and on call data dose both have immune our challenge Matrix-M in during last protection strains previously higher call than a to against responses today. detail leader preclinical older Fluzone adjuvant NanoFlu evolved and
NanoFlu induced those dose which induced neutralizing a NanoFlu In and against high against of range study a homologous influenza vaccine head-to-head dose comparison against standard recent inhibition antibodies was the broad exceeding the found and neutralized HAI influenza dose strains. that in or ferrets HAI subtypes. the the and in ferrets, activated hemagglutination antibody by responses high illustrated conducted vaccine higher Specifically, in
Fluzone leading These that NanoFlu is ferret model against the highly the that the problem address high a mismatch to elicit to XX-year licensed drifted the potential responses important suggest to call, greater challenge induce market two a in more broader NanoFlue strain antibodies against last in due we resulting in data neutralizing Also these a broad range influenza protection influenza of suggested annual a NanoFlu Since has and adults superior vaccine Sanofi's older dose. that ability influenza earnings induced have NanoFlu robust potential data achieved immune for protection milestones together its our to program. homologous has Additionally, strain. of strains. than old
were the results review in discussed Vaccine. journal published peer First, I preclinical just
to of a randomized, concentrations protection. observer-blinded, antigen evaluated trial a the assess adults. comparator-controlled The of core safety was is we will indicated, healthy be and Fluzone standard immunogenicity Stan Immunogenicity clinical of HAI dose. NanoFlu trial as trial older high Second, the The initiated using Phase in established approximately titers, [ph] adults. XXX the active objective in primary to two trial compared and X/X older industry
to announce expect We of before topline end year. data trial this the the from
Importantly, immunogenicity the vaccine. basis licensing request for trial data provide initial approval to accelerated of this may from our NanoFlu
the infants over the countries trial RSVF third its third is Prepare's XX collaboration increase moving of of our conducted Now which in from Prepare the the to in maternal Gates enrollment footprint franchise, for via of first on to Phase sites growth XXXX. global our X or in being our countries immunization expected vaccine of XX continues season the trial Foundation is enrollment. Prepare in to global its XX in to season in in five season momentum sites RSV
Spain, South India Mexico, Africa, latest New Our UK and the Zealand, Argentina, sites join Philippines, in Bangladesh Australia, the U.S. and
objective to on weeks financial the with a As maintaining to are to between trial I'll age. of conduct over demonstrated each global measures design X sites indicated include a recruited regards adults RSVF minimum estimated group-sequential minimum the RSV the as XXXX and trial a integrity call efficacy immunization Prepare XX of persistance. while utilizes a the vaccine responsive two infection medical for trial. size offering regimens. approximately RSV a of now endpoint clinical XX safety tract to randomized, the our evidence symptomatic to evolving a and older vaccinated is primary we of that of timing data season. the evaluating and events in are XX Phase adjuvant region's blinded in formulations the flexibility and of lower trial being trial of reminder, quarter. of will topline the placebo-controlled mother In significance first gestational review older turn trial that given adults dose single July trial rate based to The days from studies, players of respiratory clear the of continued is Based we is the the injection trial in efficacy results on for Participants objective life. of The older includes and through to at determine of with Prepare the immunogenicity Chris in the other maternal trial RSV for program against data analysis The XXXX. the call of benefits the the both and adults observer-blinded,
